Plasmodium falciparum merozoite surface protein 3 as a vaccine candidate: a brief review
Rev. Inst. Med. Trop. São Paulo (Online)
; 64: e23, 2022. graf
Artículo
en Inglés
|
LILACS-Express
| LILACS
| ID: biblio-1365417
Biblioteca responsable:
BR1.1
ABSTRACT
ABSTRACT Despite the many efforts of researchers around the world, there is currently no effective vaccine for malaria. Numerous studies have been developed to find vaccine antigens that are immunogenic and safe. Among antigen candidates, Plasmodium falciparum merozoite surface protein 3 (MSP3) has stood out in a number of these studies for its ability to induce a consistent and protective immune response, also being safe for use in humans. This review presents the main studies that explored MSP3 as a vaccine candidate over the last few decades. MSP3 formulations were tested in animals and humans and the most advanced candidate formulations are MSP3-LSP, a combination of MSP3 and LSP1, and GMZ2 (a vaccine based on the recombinant protein fusion GLURP and MSP3) which is currently being tested in phase II clinical studies. This brief review highlights the history and the main formulations of MSP3-based vaccines approaches against P. falciparum .
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Contexto en salud:
Agenda de Salud Sostenible para las Américas
/
Enfermedades Desatendidas
Problema de salud:
Objetivo 10: Enfermedades transmisibles
/
Malária
Base de datos:
LILACS
Idioma:
Inglés
Revista:
Rev. Inst. Med. Trop. São Paulo (Online)
Asunto de la revista:
Medicina Tropical
Año:
2022
Tipo del documento:
Artículo
/
Documento de proyecto
País de afiliación:
Brasil
Institución/País de afiliación:
Instituto Leônidas e Maria Deane/BR
/
Instituto Oswaldo Cruz/BR
/
Universidade do Estado do Amazonas/BR